Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > AGN present @ the Proactive One2One virtual investment forum

<< Previous

Bullboard Posts

Next >>

Comment by FBORBUSTon Dec 08, 2020 9:19pm

240 Views

Post# 32064464

RE:AGN present @ the Proactive One2One virtual investment forum

Good presentation, on point and covered ground.

For ~$6 million (cost of covid trial) Algernon is legitimizing itself as a company with a mission (repurposing) with an approach that gets results. Whatever the final 28 day/168 patient trial shows, it will be a major achievement for a tiny little company to have finished it's 1st phase IIb interventional trial, only 1 year after H5N1 paper!

Ifenprodil for covid is a hazardous bet, but totally justified.

Fate has blessed Algernon to the point of a data readout, hopefully fortune will smile on the results.

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant